Alessandro et al. collected plasma samples from 39 patients with advanced EGFR-mutated NSCLC treated with EGFR-TKIs, assessed the expression levels of miRNAs and found that miR-21 could be a useful indicator to monitor the effect of EGFR-TKI treatment [122]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.